heres a roundup of top developments in the biotech space over the last 24 hours corvus pharmaceuticals inc nasdaq crvs announced that its partner in china angel pharmaceuticals has treated the first patient in its phase 11b clinical trial of corvus small molecule itk inhibitor cpi818 for the treatment of relapsedrefractory tcell lymphomas in china bausch health companies inc nyse bhc in connection with its previously announced intention to separate its eye health business its wholly owned subsidiary bausch  lomb corporation has publicly filed with the securities regulator in the us and canada relating to a proposed initial public offering of bausch  lombs common shares concurrently in the us and canada all of the shares being offered will be sold by a wholly owned subsidiary of bausch health the number of common shares to be offered and the price range for the ipo have not yet been determined bausch health shares were up 093 at 27 in premarket trading lumiradx limited nasdaq lmdx announced that results from ongoing testing and monitoring of covid19 variants show its sarscov2 antigen test detects the omicron variant inhouse wet testing with live omicron virus demonstrated that the lumiradx sarscov2 antigen test detects the omicron variant with comparable sensitivity to other variants the stock was adding 108 at 933 in premarket trading swiss biopharma molecular partners ag nasdaq moln said essex woodlands health ventures funds crossed below the 3 threshold transacting its remaining shares to bvf partners lp whose holdings have now crossed the 10 threshold rising to 1221 the company has licensed its covid19 treatment candidate to novartis ag nyse nvs the stock was rallying 1075 to 3129 in premarket trading cardiovascular systems announces development of lithotripsy systems for treating calcific coronary and peripheral artery disease cardiovascular systems inc nasdaq csii a medical device company focused on peripheral and coronary artery disease announced it has made significant progress towards the commercialization of intravascular lithotripsy systems for the treatment of calcific coronary and peripheral artery disease lithotripsy is a medical procedure that uses noninvasive highpressure waves to fracture and disrupt pathologic solid masses lithotripsy has been used successfully for many years in the treatment of kidney and gall stones and more recently has found application in treatment of calcified coronary and peripheral arteries the stock was up 238 at 1850 in premarket trading